Genmab — Januar 2015
-
PEGS i Boston: Clinical Perspective of ADC Development
Michael K. Bauer, Ph.D., Senior Vice President, Clinical Development, Genmab
•Mechanism of action of HuMax-Tissue Factor-ADC
•Translation of preclinical research into the clinic
•Striking the right balance between patient safety and charting unknown clinical territory
•Beyond dose-escalation
•Patient selection - why, when and how -
Der har i lang til været fokus på defensive aktier i Danmark. Der har været mange udenlandske investorer inde at købe danske defensive aktier, blandt andet Coloplast, og det fortsætter de med, siger han.
Det er også årsagen til, at en aktie som Genmab stiger 2,6 pct. til 413,40 kr., mener chefhandleren.
-
Danske Bank har i seneste Genmab opdatering henvist til at Janssen har indgået licensaftale med Halozymes omkring deres SC teknologi http://www.halozyme.com/Technology/Enhanze-Technology/default.aspx
-
Jeg har kigget på det tidligere, Roche har adgang til 8 brug af Halozymes teknologi til 8 stoffer, de har bl a brugt det på rituxumab og herceptin.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind